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Abstract
Atherosclerotic lesions develop and progress more rapidly in diabetic patients than in nondiabetic
individuals. This may be caused by accelerated lesion formation in the high-glucose environment
of diabetes. Smooth muscle cells (SMCs) cultured in high glucose are more responsive to growth
factors such as insulin-like growth factor–1 (IGF-1). This enhanced response to IGF-1 is due in
part to increased activation of the αVβ3 integrin. We tested whether αVβ3 integrin activation was
increased in diabetic animals and whether an antibody to β3 would inhibit IGF-1 action and
development of atherosclerosis. Eight male pigs were made diabetic with streptozotocin and fed a
high-fat diet. A F(ab)2 antibody fragment directed at β3 was infused into one femoral artery,
whereas the other artery received control F(ab)2 for 3.5 months. There was a 65 ± 8% reduction in
atherosclerotic lesion area in the arteries treated with F(ab)2 antibody to β3. Phosphorylation of β3
was reduced by 75 ± 18% in vessels treated with the antibody. Shc and mitogen-activated protein
kinase phosphorylation, which are required for IGF-1–stimulated SMC proliferation, were also
significantly reduced. We conclude that activation of IGF-1 receptor and αVβ3-linked signaling
pathways accelerates atherosclerosis in diabetes and that administration of an antibody to β3 to
diabetic pigs inhibits αVβ3 activation, IGF-1–stimulated signaling, and atherosclerotic lesion
development. This approach offers a potential therapeutic approach to the treatment of this
disorder.
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Atherosclerosis is the leading cause of death for patients with both type 1 and type 2
diabetes (1). Despite the success of therapies that modify hypertension and
hypercholesterolemia, treatments that target the accelerated rate of atherosclerosis that
occurs in response to chronic hyperglycemia are not available (2). Insulin-like growth
factor–1 (IGF-1) stimulates the proliferative phase of atherosclerosis, suggesting that
inhibiting IGF-1 could prevent lesion progression (3–6). However, because IGF-1 inhibits
apoptosis in neural tissue, cartilage, and skeletal muscle, targeting the IGF-1 receptor could
lead to unacceptable toxicity (7, 8). Consequently, there is a need for a more selective way
to inhibit IGF-1 action.
In contrast to the IGF-1 receptor, expression of αVβ3 integrin is limited to three cell types:
endothelium, smooth muscle, and osteoclasts. The abundance of αVβ3 is increased in
atherosclerotic lesions, and ligands for αVβ3, such as osteopontin and thrombospondin, are
also increased in arteries from diabetic animals (9–12). Interaction between the IGF-1
receptor and αVβ3-linked signaling pathways enhances IGF-1–stimulated smooth muscle
cell (SMC) growth and migration in vitro (13), and SMCs only migrate in response to IGF-1
when αVβ3 ligands are also present in the culture medium. Hyperglycemia causes increased
cellular secretion of αVβ3 ligands, which enhance the sensitivity of SMCs to stimulation by
IGF-1 (11, 12, 14). Blocking ligand occupancy with an antibody or peptide antagonist that
binds to αVβ3 inhibits IGF-1–stimulated proliferation of SMCs in hyperglycemia (13–15).
Several investigators have targeted, with antibodies and inhibitory peptides, the binding site
on αVβ3 for Arg-Gly-Asp (RGD) sequences of αVβ3 ligands (16–18). These RGD
antagonists can have effects other than inhibition of ligand actions. These include partial
agonist activity, αVβ3 conformational-dependent changes that alter the cellular response to
the antagonist, and binding of the antagonist to other sites on αVβ3 that can modify its
inhibitory actions (18–20). One region of αVβ3, referred to as the cysteine loop (C-loop)
region (21), is distinct from the RGD-binding site (22) and interacts with the heparin-
binding domain of vitronectin, a glycoprotein of the extracellular matrix (23). This
interaction is required for αVβ3 ligands to enhance the response of SMCs to IGF-1
stimulation in vitro, but ligand binding through the RGD-binding site does not activate this
pathway (20, 23). Therefore, targeting the C-loop region may inhibit IGF-1 signaling
without triggering the negative effects of RGD-binding site antagonists. Because all
previous studies have analyzed this interaction in vitro, we undertook this study to determine
in vivo the efficacy of a monoclonal antibody that reacts specifically with the C-loop region.
We tested whether the interaction could inhibit atherosclerotic lesion progression in a
porcine model of hyperglycemia-accelerated atherosclerosis.
RESULTS
Inhibition of β3 subunit phosphorylation and IGF-1 signaling in cultured SMCs by F(ab)2
antibody to β3
The addition of vitronectin to cultured SMC resulted in a 5.2 ± 2.4–fold (mean ± SEM, P <
0.01) increase in β3 phosphorylation, which was completely inhibited by the purified F(ab)2
(10−9 M) (Fig. 1A and fig. S1A). IGF-1 stimulated Shc phosphorylation 5.7 ± 0.5–fold, but
this increase was reduced to 2.9 ± 0.4–fold after exposure to F(ab)2 antibody to β3 (mean ±
SEM, n = 3, P < 0.01) (Fig. 1B and fig. S1B). Grb-2 recruitment to Shc was reduced from
3.8 ± 0.4–fold to 2.0 ± 0.5–fold (mean ± SEM, n = 3, P < 0.05). Phosphorylation of
extracellular signal–regulated kinase 1/2 (ERK1/2) was increased 7.6 ± 0.8–fold after 5 min
in response to IGF-1 relative to a 2.0 ± 0.2–fold increase in cultures exposed to F(ab)2
(mean ± SEM, n = 3, P < 0.01) (Fig. 1C and fig. S1C). IGF-1 increased cell number by a
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factor of 2.5, and this response was reduced significantly by the antibody (Fig. 1D and fig.
S1D).
Long-term infusion of F(ab)2 antibody to β3 and its effects on lesion progression
As for our in vitro experiments, analysis of aortic extracts from diabetic and control pigs
showed that β3 phosphorylation was markedly increased in the arteries from diabetic animals
(P < 0.001) (fig. S2). After treatment with streptozotocin, all of the animals became
hyperglycemic and mean glucose (four values per 24-hour period) increased from 62 ± 6
mg/dl to 340 ± 94 mg/dl (Table 1). Six of eight animals required daily insulin administration
to maintain glucose at <450 mg/dl. Mean glucose values ranged from 340 to 368 mg/dl
(Table 1). Weight increased progressively, which is typical for growing animals in this age
range. Both cholesterol and triglyceride concentrations were significantly increased in
response to the high-fat diet and the induction of diabetes.
To determine whether the infused C-loop F(ab)2 altered lesion progression, we compared the
area of atherosclerotic lesions from those arteries to control F(ab)2–treated arteries. The
analyses show that arteries that received control F(ab)2 developed atherosclerotic lesions
(Fig. 2, top row). Histologic evaluation shows increased neointimal formation and lipid
deposition with foam cells and a fibrous cap. Representative sections from a control F(ab)2–
treated artery from a second animal show a large proliferation lesion and similar histologic
changes (Fig. 2, second row). Sections from the contralateral artery from the same animal
that received F(ab)2 antibody to β3 show a marked reduction in lesion size (Fig. 2, fourth
row). Staining for macrophages shows that they are present in the neointima of the control
F(ab)2–treated artery (Fig. 2, third row). The sections from the artery that received the
F(ab)2 antibody to β3 show minimal macrophage accumulation (Fig. 2, fifth row) The mean
intimal area of the eight vessels that received F(ab)2 antibody to β3 was reduced by 68 ±
11% when compared to controls (Table 2). Intimal area expressed as the percentage of the
medial area was also significantly reduced (Table 2).
Proliferating cell nuclear antigen (PCNA) labeling showed that fewer, 9 ± 6% of cells, were
labeled in vessels treated with F(ab)2 antibody to β3 relative to control (for example, 19 ±
3.7%) (P < 0.01) (Table 2). These findings support the conclusion that the reduction in
neointimal area is due in large part to a reduction in cell growth.
Effect of long-term infusion of F(ab)2 antibody to β3 on IGF-1–mediated signaling events
The F(ab)2 antibody to β3 reduced β3 phosphorylation by 75 ± 18% (mean ± SD, n = 8, P <
0.01) (Fig. 3). Representative data from two antibody and two control-treated arteries are
shown in Fig. 3. Antibody treatment also reduced Shc association with SHPS-1 (49 ± 12%)
and Shc phosphorylation (79 ± 20%). C-loop antibody exposure reduced phospho–mitogen-
activated protein kinase (MAPK) by 71 ± 9%. To determine whether IGF-1–stimulated
signaling had been inhibited, we analyzed the arterial homogenates for IGF-binding protein–
5 (IGFBP-5), a protein whose synthesis is stimulated by IGF-1. Exposure to the antibody
resulted in a 67 ± 13% decrease in IGFBP-5 (mean ± SEM, n = 8, P < 0.01).
Extraction of the lesions and measurement of the antibody concentrations showed that the
arteries that received the F(ab)2 antibody to β3 had a mean concentration of 9.6 ± 2.4 × 10−9
M (mean ± SEM, n = 8). The F(ab)2 concentrations in the vessels that received control
F(ab)2 was 1.4 ± 0.2 × 10−8 M. The concentration of F(ab)2 antibody to β3 in serum from the
animals was below the limit of detection of the assay (<1.9 × 10−10 M).
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The results of this study show that administration of the F(ab)2 fragment of a monoclonal
antibody that binds to a specific domain on the β3 subunit of the αVβ3 integrin (the C-loop
region) inhibits atherosclerotic lesion progression when administered locally to
hypercholesterolemic diabetic pigs. The effect of the antibody was due in part to inhibition
of cell proliferation, although an effect on extracellular matrix accumulation and cell
migration cannot be excluded. To confirm that the difference in lesion progression was due
to inhibition of IGF-1–αVβ3 signaling, we assessed the activation state of signaling pathway
components that are increased when cultured vascular SMCs are exposed to IGF-1 and
hyperglycemia. The F(ab)2 antibody to β3 fragment inhibited β3 phosphorylation, which is
activated in lesion tissue in response to increases in αVβ3 ligands, such as osteopontin and
thrombospondin. The abundance of these ligands is increased in response to hyperglycemia.
Treatment with the F(ab)2 antibody to β3 also inhibited phosphorylation of signaling
components such as Shc and MAPK, which are stimulated in vascular SMCs in response to
αVβ3 and IGF-1 receptor stimulation and mediate increased SMC migration and
proliferation in vitro (14). Our results indicate that the concentrations of the F(ab)2 antibody
to β3 that were achieved in vivo were sufficient to suppress activation of these signaling
components. Because the antibody also inhibited atherosclerotic lesion progression
significantly, the results suggest that blocking the activation of αVβ3 in diabetic pigs results
in attenuation of lesion growth.
Previous studies have shown that αVβ3 is activated after vascular injury (for example,
balloon denudation) in mice (9). Similarly, an αVβ3 monoclonal antibody that inhibited
injury-induced activation attenuated lesion formation (16) and β3−/− mice had reduced
neointimal lesion formation in response to carotid artery injury (24). A study with a vascular
stenosis model demonstrated that an αVβ3 antagonist attenuated neointimal expansion in
pigs (17). β3-Integrins are up-regulated after vascular injury in baboons, and β3 up-
regulation enhances the SMC response to thrombospondin or thrombin (25). Growth factors
that stimulate SMC growth, such as transforming growth factor–β and platelet-derived
growth factor (PDGF)–BB, enhance β3 expression (26). Two different αVβ3 monoclonal
antibodies inhibited human coronary SMC migration (27). Furthermore, treatment of
patients undergoing angioplasty and stent placement with abciximab (a monoclonal antibody
that binds to αIIB β3) decreases the need for revascularization (28). Our results show that
inhibiting ligand binding to αVβ3 inhibits lesion progression in a diabetic animal model,
extending previous work to a model in which progression of atherosclerosis is exacerbated
by chronic hyperglycemia.
The mechanisms by which hyperglycemia leads to αVβ3 activation are not well
characterized. Endothelial cells that express αVβ3 are stimulated to migrate in the presence
of hyperglycemia (29), and αVβ3 expression is up-regulated in endothelium and
microvascular SMC in diabetes (30, 31). The ligands that bind to αVβ3 are also up-regulated.
Osteopontin concentrations are increased in tissues from diabetic animals, as are
thrombospondin and connective tissue growth factor (32–35), and vascular SMCs in culture
exposed to hyperglycemia secrete increased amounts of thrombospondin, osteopontin, and
vitronectin (14). That the increase in αVβ3 ligands is functionally relevant is demonstrated
by our observation that β3 phosphorylation is constitutively increased in arteries from
diabetic pigs (fig. S2). The importance of β3 phosphorylation was proven by mutating the
two key tyrosines in its cytoplasmic domain and showing that SMCs expressing that mutant
were refractory to the sensitizing effect of hyperglycemia on IGF-1–stimulated cell
proliferation (36). This activation of β3 is mediated by binding the C-loop domain (21).
Indeed, our data show that the monoclonal antibody used in this study inhibits the ability of
IGF-1 to stimulate Shc and MAPK phosphorylation, as well as cellular proliferation (Fig. 1).
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Other investigators have demonstrated that antibodies to αVβ3 inhibit mesangial and SMC
growth or migration in vitro in response to hypoxia plus hyperglycemia (37). Although the
responses to other growth factors are enhanced in the presence of hyperglycemia, this occurs
by different mechanisms. For example, hyperglycemia enhances the ability of PDGF to
stimulate autophosphorylation of the PDGF receptor, which leads to mitogenesis (38), but
this response does not depend on αVβ3 ligand occupancy.
After mechanical injury (denudation of the interior wall of the vasculature with a balloon
catheter), vascular cells show an increase in IGF-1 synthesis (39, 40), and overexpression of
IGF-1 by SMC results in an enhanced proliferative response to balloon injury (3). Similarly,
somatostatin analogs, which decrease IGF-1 synthesis by SMC, inhibit human coronary
SMC proliferation (41). In contrast, previous in vitro studies showed that hyperglycemia
enhances IGF-1 signaling responses via increased ligand occupancy of αVβ3 but that there is
no alteration in IGF-1 receptor abundance or in its activation (14). Our study shows that, if
only αVβ3 and not the IGF-1 receptor is inhibited, both neointimal lesion size and IGF-1
signaling are reduced. These results suggest that chronic activation of αVβ3 is required to
enhance cellular signaling in response to IGF-1 and that this activation stimulates cellular
accumulation in the neointima. Our results do not exclude the possibility that inhibiting
IGF-1 receptors would also contribute to attenuation of atherosclerotic lesion formation, but
they do suggest that when hyperglycemia is present interrupting only one limb of the
pathway is adequate for lesion inhibition. Because αVβ3 functions cooperatively by
enhancing response to IGF-1 during hyperglycemia, this antibody provides a useful research
tool for examining whether it can reduce the sensitivity of vascular cells to IGF-1 to a level
that approximates their normal physiologic response to IGF-1 stimulation.
Hormones that induce stress in vascular wall cell types, such as angiotensin II and
aldosterone, increase IGF-1 receptor synthesis (42). A stable peptide analog of IGF-1 that
inhibited IGF-1 binding to the IGF-1 receptor inhibited SMC proliferation after balloon
injury in the rat (43). These findings suggest that it would be logical to target the IGF-1
receptor directly to inhibit atherosclerosis. However, because IGF-1 receptors are expressed
ubiquitously, this approach could lead to other deleterious effects. IGF-1 has anabolic and
antiapoptotic effects in skeletal muscle, bone, and brain (44). Furthermore, inhibitors of the
IGF-1 receptor tyrosine kinase also inhibit the insulin receptor tyrosine kinase, which could
exacerbate deteriorating glucose control (45). Therefore, our strategy to target αVβ3, an
integrin co-receptor that is expressed in only three cell types, reduces the risk of inducing
these unwanted responses. Nevertheless, even an antibody with this narrow spectrum of
activity could induce side effects (for example, inhibition of bone resorption or inhibition of
premenstrual angiogenesis in the uterus). These potential side effects would need to be
investigated before clinical application.
In addition to potential off-target effects, several questions need to be addressed before
translation of these findings to the treatment of humans with atherosclerosis. Initially, it will
be important to determine whether the antibody can inhibit atherosclerosis in patients with
diabetes who do not have hyperlipidemia. Selection of the appropriate patient population for
analysis (for example, patients with established atherosclerosis and proliferative disease)
will also be important. Finally because IGF-1 also has antiapoptotic effects and rapid
induction of apoptosis has been proposed to lead to plaque rupture (46), patients who are
being treated with integrin inhibition will need to be carefully monitored for this potential
complication.
Our studies demonstrate that blocking ligand binding to the C-loop region of αVβ3 results in
attenuation of the accelerated atherosclerosis that occurs in a porcine model of diabetic
atherosclerosis. These effects are mediated in part by blocking the hyperglycemia-induced
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enhancement of cellular responsiveness to IGF-1. Inhibiting the αVβ3 receptor with a
monoclonal antibody that binds to a specific site on the β3 subunit is a promising approach
for treatment of proliferative phase of this disease in patients with diabetes.
MATERIALS AND METHODS
Materials
Polyvinyl difluoride membranes (Immobilon P) were purchased from Millipore.
Autoradiographic film was from Pierce. Fetal bovine serum, Dulbecco’s modified Eagle’s
medium (DMEM), penicillin, and streptomycin were from Life Technologies. The
phosphotyrosine antibody (PY99) was from Santa Cruz Biotechnology. The polyclonal
antibody against β3 was prepared as described (14). Phospho-ERK1/2, total ERK1/2, and
antibodies to Grb-2 and Shc were from BD Transduction Laboratories. The antibody to
SHPS-1 was from Upstate. Secondary antibodies were from Jackson ImmunoResearch. All
other reagents were purchased from Sigma Chemical unless otherwise stated. Porcine aortic
SMCs were isolated and maintained in 4.5 g of DMEM per liter of glucose (47). Cells were
used between passage 5 and passage 16.
Generation and purification of the monoclonal C-loop antibody to β3 and the F(ab)2
fragment
Four BALB/c mice were immunized with a peptide immunogen–keyhole limpet
hemocyanin (KLH) conjugate (23). A high-producing monoclonal antibody clone was
generated and selected (14). The clone was expanded in medium containing 10% low
immunoglobulin G (IgG) (Gibco) serum, interleukin-6 bovine (10 μg/ml) (Roche),
glutamine (4 mM), penicillin (500 U/ml), and streptomycin (200 μg/ml) (Gibco) to a density
of 2.5 × 105 cells/ml; transferred to 2-liter roller bottles; and maintained at that density by
adding fresh media every 48 hours until the volume reached 600 ml. A total of 10 l of
conditioned medium, which contained 720 mg of the antibody, was collected and then
concentrated by ammonium sulfate precipitation.
The enzyme ficin linked to agarose (200 ml) (Pierce-Thermo Fisher) was washed and
activated (48). The ficin agarose was incubated with the ammonia sulfate precipitate (3 mg/
ml) for 96 hours at 37°C. After incubation, the digested IgG was applied to a protein A
affinity column to remove noncleaved, intact IgG and Fc fragment. The flow-through
material containing F(ab)2 was purified by protein G–Sepharose followed by an affinity
column that had been prepared by conjugating the C-loop domain peptide to Sepharose. The
material was eluted in 0.5 M Na2PO4 (pH 3.0) and then analyzed by SDS–polyacrylamide
gel electrophoresis (PAGE) with immunoblotting for IgG as well as silver staining. A single
band (molecular weight estimate of 120 kD) was detected. Immunoblotting confirmed that it
was a F(ab)2 fragment. Immunoblotting with Fc antibodies showed that >99.6% of the Fc
fragment was removed and <0.1% of intact IgG remained. The recovery was 42%. The
affinity as calculated by Scatchard analysis was 1.2 × 109. The F(ab)2 fragment from the
control antibody prepared by immunizing mice with KLH was purified using the same
method.
Enzyme-linked immunosorbent assay method
A 96-well Immulon IV plate (Fisher) was coated with CYDMKTTC immunogen peptide
(50 μg/ml) conjugated to bovine serum albumin (BSA). After washing (0.05% Tween) and
blocking (2% BSA), the samples were added and incubated for 1 hour at 22°C. An alkaline
phosphatase–conjugated secondary antibody (goat antibody to mouse; Jackson
ImmunoResearch) was added followed by diethanolamine developer (50 μl per well)
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containing p-nitrophenyl phosphate for 15 min, and the results were determined by
spectrophotometry at 405 nm.
Testing of purified β3 C-loop F(ab)2 antibody
Quiescent SMCs (5 × 106 cells per 10-cm dish) were incubated in serum-free medium and
02% BSA overnight. Control or β3 C-loop F(ab)2 (10−9 M) was added for 4 hours followed
by IGF-1 (50 ng/ml). To examine β3 phosphorylation, we added vitronectin (1 μg/ml) 3
hours after addition of the antibody and the incubation continued for 60 min. SMCs were
lysed in modified radioimmunoprecipitation assay (RIPA) buffer and analyzed by
immunoblotting with the appropriate antibody (14). For immunoprecipitation studies, cell
lysates were incubated overnight at 4°C with the appropriate antibody (for example, β3 or
Shc), immune complexes were precipitated with protein A–Sepharose, the pellets were
resuspended in 45 μl of Laemmli buffer with 0.2 M dithiothreitol, and the proteins were
immunoblotted (14). Cell proliferation assays were performed as described (49). The C-loop
β3 F(ab)2 antibody was added (10−9 M) immediately before the addition of IGF-1. Cell
number was determined after 48 hours.
Induction of diabetes and antibody administration
Male Yorkshire pigs (12 months old; n = 8) were purchased from the Clemson University.
They were maintained according to the Guide for Care of Laboratory Animals [National
Institutes of Health (NIH) publication #85-23]. Eight pigs were placed on a high-fat diet
containing 1% cholesterol, 20% beef tallow, and 0.75% cholic acid for 4 weeks. This diet
induces increases in cholesterol and oxidized low-density lipoprotein (50). Vascular
cholesterol deposits and foam cell deposition are detected after 8 weeks (50).
The animals received streptozotocin (50 mg/kg per day) intravenously for 3 days. Fasting
glucose rose from 81 ± 11 mg/dl to 360 ± 123 mg/dl after 7 days. Two weeks later, all
animals had catheters placed within the walls of both femoral arteries, with luminal opening
placed into the arterial medial layer. The catheter was sutured into the adventitia, and a 2-ml
Alzet minipump was placed in the subcutaneous space. The pump reservoir in one artery
was filled with 2.0 ml of phosphate-buffered saline containing 0.7 mg of the C-loop β3
F(ab)2 antibody. The contralateral artery received 0.7 mg of control F(ab)2. The locations of
the treatments were randomized. Each artery received 23 μg per day for 30 days. A total of
eight vessels received this dose of β3 F(ab)2 antibody and eight received the control. After
30 days, the pump reservoirs were exchanged and replacement solution of antibody was
infused for an additional 30 days. This was continued for 3.5 months. This time interval was
chosen because the investigators who developed this model showed that proliferative lesions
developed over this interval and that a clear difference could be detected when diabetic and
nondiabetic animals were compared (51).
Preparation of arteries for analysis
After euthanasia, femoral arteries were collected and processed as follows: (i) An open
femoral artery was prepared for photography of raised atherosclerotic plaques; (ii) the
section at the site of needle insertion was embedded in optimal cutting temperature
(compound); (iii) the section distal to the needle insertion site was divided into 0.5-cm
segments, frozen in liquid nitrogen, and stored at −80°C before biochemical analysis; and
(iv) the segments proximal to the needle insertion site were placed in 10% buffered formalin
and then 20 sections were taken at 50-μm intervals.
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Arterial sections were stained with Verhoeff–van Gieson to highlight the internal elastic
lamina (IEL) and external elastic lamina (EEL). The image of each cross section was
digitized and analyzed with an image analyzer (Nikon Microphot FXA microscope) with
Optronics TEC 470CCD video camera system. Images of EEL, IEL, and lumen were
captured and analyzed with NIH Image software (4, 17). The neointimal, luminal, and total
cross-sectional areas were calculated. The neointimal area is the area inside the IEL minus
the luminal area. The medial area is the total cross-sectional area minus the area inside the
IEL. The observers were blinded as to treatment group. An average of 12 sections was
analyzed per vessel. For statistical comparison of lesion area, the data were analyzed with
two-way analysis of variance. Step-down tests, including t tests, were used for individual
comparisons. To detect macrophages, we incubated the tissue sections with a 1:100 dilution
of SRA-E5 (Cosmo Bio), a monoclonal antibody that detects the porcine macrophage
scavenger receptor, for 1 hour at 22°C (4). This was followed by incubation with horse
antibody to mouse IgG and Vectastain Elite avidin-biotin complex (ABC) reagents supplied
in the Vectastain Universal Elite ABC kit (Vector Laboratories). The stain was visualized
with NovaRED (Vector Laboratories) and counterstained with hematoxylin.
PCNA staining
Serial sections (5 μm thick) were obtained from paraffin-embedded vessels. Five sections
per animal (every 10th section) was incubated with a 1:100 dilution of PCNA antibody
(Dako) for 1 hour at 22°C followed by ABC Vectastain horse antibody to rabbit IgG
secondary antibody. Staining was visualized with the chromogen diaminobenzidine (Vector
Laboratories). The number of cells staining positive in the neointima was determined and
expressed as a percentage of the total number of SMCs that were counted per section.
Biochemical analysis of arteries
Arterial samples were homogenized in modified RIPA buffer containing phosphatase and
protease inhibitors (21). Protein abundances were determined with a bicinchoninic acid
assay (Pierce). The procedures used for immunoprecipitation or immunoblotting of the
tissue lysates were as described (21, 23).
Chemiluminescent images were scanned with a DuoScan T1200 (AGFA), and band
intensities of the scanned images were analyzed with NIH Image version 1.61. The
Student’s t test was used to compare differences between treatments. The results that are
shown are representative of at least three separate analyses.
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Refer to Web version on PubMed Central for supplementary material.
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Effect of F(ab)2 against C-loop of β3 on IGF-1 signaling events. (A) SMCs were exposed to
the C-loop β3 F(ab)2 (10−9 M) for 2 hours before a further 2-hour incubation with vitronectin
(Vn) (1 μg/ml). After immunoprecipitation (IP) with antibody to β3, β3 phosphorylation was
visualized by immunoblotting (IB) with an antibody to phosphotyrosine (p-Tyr). Lysates
were also immunoblotted directly with an antibody to β3 to control for differences in protein
loading. (B) Cells were treated with or with-out the C-loop β3 F(ab)2 (10−9 M) for 4 hours
followed by IGF-1 (50 ng/ml). Shc phosphorylation was determined by immunoprecipitation
with an antibody to Shc and immunoblotting with an antibody to phosphotyrosine (top). Shc
association with Grb-2 was determined by immunoprecipitation with an antibody to Shc and
immunoblotting with an antibody to Grb-2 (middle). To control for loading, we reprobed
blots with an antibody to Shc (bottom). (C) SMCs were treated with or without C-loop β3
F(ab)2 (10−9 M) for 4 hours followed by the addition of IGF-1 (50 ng/ml). After lysis,
proteins were separated by SDS-PAGE before immunoblotting with an antibody to phospho-
ERK1/2 (pERK) or total ERK. (D) SMCs (2 × 104) were plated in each well of a 24-well
plate before exposure to IGF-1 (50 ng/ml) in the presence or absence of the C-loop β3 F(ab)2
(10−9 M). After 48 hours, cell number was determined. ***P < 0.001 when proliferation in
the presence of IGF-1 is compared with control.
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Photomicrographs of the atherosclerotic lesions. (A) Features of atherosclerotic plaques in
femoral arteries treated with control F(ab)2. Left, Verhoeff–van Gieson stain. Arrows,
fibrous cap; asterisk, necrotic cells; circles, disrupted IEL + medial thinning. Scale bars, 400
μm (left) and 100 μm (middle and right). Middle, hematoxylin and eosin (H&E) stain.
Arrows, foam cells. Right, stained with antibody to macrophage scavenger receptor
(SRA-35). Arrows, positively stained cells. (B) A control artery from a different animal.
Left, stained with H&E. Asterisk, well-developed fibrous cap. Middle, enlargement of same
areas as in the left panel. Right, enlargement of boxed area in middle panel. Arrow, foam
cell. (C) Sections adjacent to these shown in (B) stained with antibody to macrophage
scavenger. Middle, enlargement of left panel. Right, boxed area from middle panel. Arrows,
positively stained cells. (D) A F(ab)2 anti-β3–treated artery from the same animal as shown
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in (A) stained with H&E. (E) Sections from the same artery stained with the antibody to
macrophage scavenger receptor. No macrophages were detected in the artery treated with
F(ab)2 antibody to β3. (B to E) Scale bars, 500 μm (left), 250 μm (middle), and 125 μm
(right).
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Effect of infusion of F(ab)2 against the C-loop of β3 on IGF signaling events in porcine
arteries. (A) Tissue homogenates from the femoral arteries were either directly
immunoblotted with the appropriate antibody or used for immunoprecipitation before SDS-
PAGE and immunoblotting. The proteins that were detected are listed in the left panel.
Lanes 1 and 2, lesion homogenates from arteries that received control F(ab)2; lanes 3 and 4,
lesion homogenates from arteries that received the C-loop F(ab)2 antibody to β3. (B) The
table shows the mean ± SD results from all eight animals.
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Table 2
Morphometric analysis of femoral arteries.
Treatment Vessels (n) Intimal area, μm2 (mean ± SD) Intimal area, % of medial area (mean ± SD) % PCNA
F(ab)2 antibody to β3 8 59,438 ± 7,132* 9.3 ± 2.8† 3.1 ± 4.2%*
Control 8 132,086 ± 19,041 21.1 ± 3.2 19.3 ± 3.7%
*
P < 0.01 versus control.
†
P < 0.05 versus control.
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